Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
382 studies found for:    gefitinib
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gefitinib retreatment
2 Unknown  Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib, Hydroxychloroquine
3 Completed Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Condition: Myelogenous Leukemia, Acute
Intervention: Drug: gefitinib
4 Unknown  First Line Gefitinib by FDG-PET Metabolic Response
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib
5 Unknown  High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Gefitinib
6 Completed A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: celecoxib, gefitinib
7 Suspended Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: gefitinib
8 Unknown  Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Gefitinib
9 Recruiting PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib
10 Completed
Has Results
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
Condition: Lung Cancer
Intervention: Drug: Gefitinib 250mg
11 Unknown  Third-line Treatment of Gefitinib in NSCLC Patients
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Gefitinib
12 Completed
Has Results
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib;   Drug: Placebo
13 Completed Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
14 Recruiting High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
Conditions: Self Efficacy;   Drug Toxicity
Intervention: Drug: Erlotinib or Gefitinib
15 Completed
Has Results
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Neoplasms
Intervention: Drug: Gefitinib
16 Completed Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib and Nimotuzumab;   Drug: Gefitinib
17 Unknown  Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Brain Metastasis
Intervention: Drug: gefitinib
18 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
19 Recruiting A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Condition: EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Interventions: Drug: Apatinib;   Drug: Gefitinib;   Drug: Placebo
20 Completed Gefitinib in Treating Children With Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gefitinib;   Other: pharmacological study;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.